|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Bristol-Myers Squibb Company (BMY) Posts $711 Million Loss From Generic Plavix Cutting Sales, Research Charge
10/24/2012 8:16:20 AM
Drugmaker Bristol-Myers Squibb Co. posted a rare loss in the third quarter as U.S. sales hemorrhaged due to new generic competition to blood thinner Plavix and the company took a big charge for a failed research project. The company slashed its profit forecast for the full year, and its shares fell more than 2 per cent in premarket trading. The maker of diabetes drug Onglyza said Wednesday that it lost $711 million, or 43 cents per share. A year ago, the New York-based company posted net income of $969 million, or 56 cents per share. Excluding the charge, net income would have been $685 million, or 41 cents per share, a penny below analysts' expectations of 42 cents. Total revenue fell 30 per cent, to $3.74 billion, short of the $4 billion analysts anticipated. That was mainly because revenue from blood thinner Plavix, which had been the world's second-bestselling drug until U.S. generic competition hit in May, dropped 96 per cent in the July-September quarter to $64 million. Total U.S. sales dropped an astounding 43 per cent, to $2 billion, as generic competition to two other big sellers piled on. Those are blood pressure drugs Avapro and Avalide, whose combined sales fell 56 per cent to $96 million. Fellow drugmaker Eli Lilly likewise was hurt by generic competition — to its all-time bestseller, the antipsychotic Zyprexa, whose sales fall 68 per cent to $374.5 million. Its net income rose slightly, though, on a drop in expenses and a one-time gain.
|
|
|
|
|
|
|
|
|
|
|